Why Scholar Rock (SRRK) Is Up 13.0% After FDA Priority Review for Apitegromab in SMA
- Earlier this month, Scholar Rock announced that positive Phase 3 SAPPHIRE trial results for its muscle-targeted therapy apitegromab in children and adults with spinal muscular atrophy (SMA) were published in The Lancet Neurology, also noting its Biologics License Application was accepted by the FDA for priority review.
- This marks apitegromab as the first muscle-targeted treatment candidate for SMA to achieve clinical success at a pivotal trial stage, further recognized by multiple special FDA and EMA designations.
- We’ll explore how the acceptance of apitegromab’s FDA application shapes Scholar Rock’s investment picture and outlook for rare disease therapies.
Find companies with promising cash flow potential yet trading below…
